PMC:7787218 / 12687-14333 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"196","span":{"begin":34,"end":44},"obj":"Species"},{"id":"197","span":{"begin":127,"end":137},"obj":"Species"},{"id":"198","span":{"begin":1253,"end":1263},"obj":"Species"},{"id":"199","span":{"begin":1444,"end":1465},"obj":"Species"},{"id":"200","span":{"begin":1541,"end":1549},"obj":"Species"},{"id":"201","span":{"begin":414,"end":421},"obj":"Disease"},{"id":"202","span":{"begin":1094,"end":1102},"obj":"Disease"},{"id":"203","span":{"begin":1608,"end":1616},"obj":"Disease"}],"attributes":[{"id":"A196","pred":"tao:has_database_id","subj":"196","obj":"Tax:2697049"},{"id":"A197","pred":"tao:has_database_id","subj":"197","obj":"Tax:2697049"},{"id":"A198","pred":"tao:has_database_id","subj":"198","obj":"Tax:2697049"},{"id":"A199","pred":"tao:has_database_id","subj":"199","obj":"Tax:2697049"},{"id":"A200","pred":"tao:has_database_id","subj":"200","obj":"Tax:9606"},{"id":"A201","pred":"tao:has_database_id","subj":"201","obj":"MESH:D009369"},{"id":"A202","pred":"tao:has_database_id","subj":"202","obj":"MESH:C000657245"},{"id":"A203","pred":"tao:has_database_id","subj":"203","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"If a person has a reaction to one SARS-CoV-2 vaccine, what are the implications for the safety of vaccination with a different SARS-CoV-2 vaccine? Furthermore, what safety issues may preclude future vaccination altogether? Indeed, mRNA vaccines are a promising new technology, and demonstration of their safety is relevant to the development of vaccines against several other viruses of global importance and many cancers.7 For the immediate future, during a pandemic that is still increasing, it is critical that we focus on safe and efficient approaches to implementing mass vaccination. In the future, however, these new vaccines may mark the beginning of an era of personalized vaccinology in which we can tailor the safest and most effective vaccine on an individual and a population level.17 Moreover, postvaccination surveillance and documentation may present a challenge. On a public health level, the Vaccine Adverse Event Reporting System (VAERS; https://vaers.hhs.gov) is a national reporting system designed to detect early safety problems for licensed vaccines, but in the case of Covid-19 vaccines, the system will serve the same function after an EUA has been issued. On an individual level, a system that will keep track of the specific SARS-CoV-2 vaccine received and will provide a means to monitor potential long-term vaccine-related adverse events will be critical to individual safety and efficacy. V-safe (https://cdc.gov/coronavirus/2019-ncov/vaccines/safety/vsafe.html) is a smartphone application designed to remind patients to obtain a second dose as needed and to track and manage Covid-19 vaccine–related side effects."}

{"project":"LitCovid-sentences","denotations":[{"id":"T44","span":{"begin":0,"end":146},"obj":"Sentence"},{"id":"T45","span":{"begin":147,"end":222},"obj":"Sentence"},{"id":"T46","span":{"begin":223,"end":589},"obj":"Sentence"},{"id":"T47","span":{"begin":590,"end":879},"obj":"Sentence"},{"id":"T48","span":{"begin":880,"end":1182},"obj":"Sentence"},{"id":"T49","span":{"begin":1183,"end":1419},"obj":"Sentence"},{"id":"T50","span":{"begin":1420,"end":1646},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"If a person has a reaction to one SARS-CoV-2 vaccine, what are the implications for the safety of vaccination with a different SARS-CoV-2 vaccine? Furthermore, what safety issues may preclude future vaccination altogether? Indeed, mRNA vaccines are a promising new technology, and demonstration of their safety is relevant to the development of vaccines against several other viruses of global importance and many cancers.7 For the immediate future, during a pandemic that is still increasing, it is critical that we focus on safe and efficient approaches to implementing mass vaccination. In the future, however, these new vaccines may mark the beginning of an era of personalized vaccinology in which we can tailor the safest and most effective vaccine on an individual and a population level.17 Moreover, postvaccination surveillance and documentation may present a challenge. On a public health level, the Vaccine Adverse Event Reporting System (VAERS; https://vaers.hhs.gov) is a national reporting system designed to detect early safety problems for licensed vaccines, but in the case of Covid-19 vaccines, the system will serve the same function after an EUA has been issued. On an individual level, a system that will keep track of the specific SARS-CoV-2 vaccine received and will provide a means to monitor potential long-term vaccine-related adverse events will be critical to individual safety and efficacy. V-safe (https://cdc.gov/coronavirus/2019-ncov/vaccines/safety/vsafe.html) is a smartphone application designed to remind patients to obtain a second dose as needed and to track and manage Covid-19 vaccine–related side effects."}